{"name":"Sierra Oncology LLC - a GSK company","slug":"sierra-oncology-llc-a-gsk-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Placebo to match danazol","genericName":"Placebo to match danazol","slug":"placebo-to-match-danazol","indication":"Control arm in phase 3 clinical trial comparing danazol efficacy","status":"phase_3"},{"name":"Placebo to match ruxolitinib","genericName":"Placebo to match ruxolitinib","slug":"placebo-to-match-ruxolitinib","indication":"Myelofibrosis","status":"phase_3"}]}],"pipeline":[{"name":"Placebo to match danazol","genericName":"Placebo to match danazol","slug":"placebo-to-match-danazol","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration of danazol for use as a control in clinical trials.","indications":["Control arm in phase 3 clinical trial comparing danazol efficacy"],"catalyst":""},{"name":"Placebo to match ruxolitinib","genericName":"Placebo to match ruxolitinib","slug":"placebo-to-match-ruxolitinib","phase":"phase_3","mechanism":"This drug is a placebo used to match the effects of ruxolitinib.","indications":["Myelofibrosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOVlpoVjU1REoyTnlzUklrU2xDU0oydEhNXzNteTZOOWFuRGxmcEkyVVlHcHMtUDZyaVkzNGx3dmY1UTVMV3NReEwxUElwYWwyUUJtVVZsTjdqLURBMGlHa01ncnc1MFpZVWZtUDFtLTBBX3ZiQ1AxV0xfYk8wTzI4MENsNElwalJkNnU2akJ3bHB4QQ?oc=5","date":"2026-02-04","type":"deal","source":"Fierce Biotech","summary":"GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' - Fierce Biotech","headline":"GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9QamdER3pWa3d3X01DeThMbEZXbXA3QTRvazZWczE3TnUwd2JQN1I3a2szVWJCd3dBYnpNR2dPVG9DUmRGbDJNU0hPVVM1VHR0Q0lB?oc=5","date":"2025-01-09","type":"pipeline","source":"FirstWord Pharma","summary":"Friday Five – JPM preview, GSK gets a GIST, J&J guns for Tagrisso…and more - FirstWord Pharma","headline":"Friday Five – JPM preview, GSK gets a GIST, J&J guns for Tagrisso…and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPRU1qRi1VQkpCYWtPX1owVlVSNDE5QUhGOERCWkZQaGxiNzdKNXF4VlNsRVdJbEZHNlk3Wm1kNEgwNUxENmgzYUdCNFVpTC1HbTNSZ29JN1pHNnE1S0oxMFpXZHFDMjNrOUxyNUlNZkk4SXFib2R2c3ZBdU4tVUZnSDljdHpuNFNSdzRzSXh3WlBhUndheXJNQkdQQnIwMXFUUG5XY2RpLTMwYnBxUDR2Q1N4bENVS0E?oc=5","date":"2023-09-15","type":"regulatory","source":"Fierce Pharma","summary":"In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use - Fierce Pharma","headline":"In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQ285WWZ3RjNWb29GeGs5TTVsWkQ3WTEwcVZOTXhtOTdreWI5Tm9hTG9uTVZUYldCSVVnZmNoRDBBOUc3VjJrWEptSTlKR3R0em5kNmQyYU5LR0pRa1dWTlIxRnExREMzVXpJRFV6SERVOWs1dXZKS3NBOXBqMTY2NUtUeFh1WGRZODRJMV92MWhCUFludVNfZC1WUFdiSW9CRlg0NjhpOGRaLTlJb2tQei1CTlFKVjFNeTg1QlJXVjNHZw?oc=5","date":"2023-02-02","type":"pipeline","source":"Reuters","summary":"GSK gives few clues on plans to replenish medicine cabinet - Reuters","headline":"GSK gives few clues on plans to replenish medicine cabinet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9IcXpFZ2p5MUpLVkVPYTdLTUE0WkN3RmV4LS1Cd0pOQlhlamlmc0tyRjBnUjNKbzdZblE1eDh0YmttZXRxMXRITk10cGVyRHMwQjdmMzZvRzAxSkhZSFRyUy1tVTh3eFU?oc=5","date":"2023-01-30","type":"deal","source":"Fierce Pharma","summary":"The top 10 biopharma M&A deals of 2022 - Fierce Pharma","headline":"The top 10 biopharma M&A deals of 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNckQ1NDZIYVpBeXNfdGV5emVlQnlXMkFjS195ZXViWkx3WWJoaERUNVpNUFFvYlNONXNGdk85dkpWLWNrLTZSaFhITGtUc21SbDZRUTB3Z0tPd1pHN0gtQ2UzZ2RPbGdzbi1JNThXaTlNSW5qaGpqamRuRVpUVGxieG1KWEZoZkRrX2hPcldLQXRhN2pjay1KNDVwYjZ6X2c0ZlZ4Sk03R1Q1Y015Nk0wX2puY2twQU5oRkpJTHNUNFctLXRvbWpv?oc=5","date":"2023-01-11","type":"pipeline","source":"Fierce Pharma","summary":"JPM23: GSK's Luke Miels on RSV and mRNA vaccines, Blenrep and Zejula withdrawals, plus more - Fierce Pharma","headline":"JPM23: GSK's Luke Miels on RSV and mRNA vaccines, Blenrep and Zejula withdrawals, plus more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1fdHhBcTh4U2wwUDVoNEpiYmtfVGdnNDk3SHdIWnJhOFBYRUhCbjhSOW53LUxRNDQ5by1GbFQwZDlzLVFfZDNXbjFqTGw5QmJsOWIwVi04TDBsWWNhRTNOZ3prY1YzZGxIQlZrUjNpc1ZuQ01OVzc3VnFIWQ?oc=5","date":"2022-12-16","type":"deal","source":"drugdiscoverytrends.com","summary":"The top 10 pharma M&A deals of 2022 - drugdiscoverytrends.com","headline":"The top 10 pharma M&A deals of 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5YQUhYb3pSOGtlQnNCNUVXS3hQUFlFajRpMjBpVGdEby1oYmVZbnU4Q1lQS1RnWG1KM29HdmhMZGo0d19aanBXUGFVdERUNFFOQV9BUjF1UHd1WVBDWkRZM0VfTmN1aEdCRllxcDJsYTFySkt6TEg0X013?oc=5","date":"2022-10-11","type":"pipeline","source":"PharmaLive","summary":"GSK 2022: A newly focused biopharma company - PharmaLive","headline":"GSK 2022: A newly focused biopharma company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNZDFXaVdBUTkxZjcwY2FMb2QtTTFHWE1tUl9icDdVZkJJYlRXYjdrXzd1aE1ZNXNfdXJfeFBrR3lxRFZjdzNya3pmWV9tdnVYUC1mbktFazJKa0VCNTk4VGRKS0ZvRmVqclp3dTEtUjl4TTRqQ3hZWHlqNVo1WjNwekIxOUJ2bU83dkROX0xuX0RxUjFIcFY3ZmgtakszdkJRd2pCSks2Uk1MYUhibmc?oc=5","date":"2022-05-16","type":"deal","source":"Pharmaceutical Technology","summary":"These were the biggest pharmaceutical deals in early 2022 - Pharmaceutical Technology","headline":"These were the biggest pharmaceutical deals in early 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNbnlxNEEtV2dYSWRRakpvX3E1RVpWYU5HOUU5Y2xkN0FyUWlpSjBISzZueXNqLUdZNmxYdGRoTl9jdVN6SkFfaEdjbkw1WjBsWTRWckRfSkxMQWZXYl9SQmxsRWRDY05jVmdiNjNqRDNBTnlCVzJWd091Y1VfUndUQnFmaGpQbnFRaFNQTG1LTzdROXFncGgyOW5pSUF0Tk9naFlEekJvMA?oc=5","date":"2022-05-03","type":"deal","source":"Fierce Biotech","summary":"Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be - Fierce Biotech","headline":"Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUDdGLWJvMGpack05N0tvTUNUTTVxUWY0aW9RRVdFN0t2b2NXa2UzM3pXYThGdldpdlJ4N1F4MF9rMG5VWlU5TDAtR1BxTWZnT0FXRFNtazl1QnF5TUoxdHRoWGFWV1dpaUVRR0NNbzJqNXl5ZVFqY1lnNlpUNmFDcnEyaW43MXVmTTM4bU04OWVwdkhUNno4ZmJuVk15akt1TEU3V0s5dGkxQQ?oc=5","date":"2022-04-13","type":"deal","source":"Reuters","summary":"GSK to buy Sierra Oncology amid pressure to boost drug pipeline - Reuters","headline":"GSK to buy Sierra Oncology amid pressure to boost drug pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNWTBWNUpHZXJyb3E4MUNNX3pJVFRzZjc4bV9jeTJLOFNfWGJIVENpTVlvekhINGVNcW43SUJKSHR5dVBfRnVRYS13VmRGUVZ0QVFRSGtvUmhtbnhaYlB2bkhWT0RyNllQNHVIY2w5UzYyeXhGWjVxcDlIWDYwLWlwZ2p4UmFTTHRhRTZ6b3FFc2ZfMm9KeTZyOHVFakNDcmJ0MGppUjh4TUFBc1gwYWREYzJRTQ?oc=5","date":"2022-04-13","type":"deal","source":"Fierce Biotech","summary":"GSK inks $1.9B Sierra takeover as $3M bet on Gilead castoff turns into blockbuster buyout - Fierce Biotech","headline":"GSK inks $1.9B Sierra takeover as $3M bet on Gilead castoff turns into blockbuster buyout","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}